Impact of varying health status thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis

<bold>Objectives:</bold> In progressive disease such as COPD, patient expectations can be low so attaining disease stability (DS) should be considered important. DS includes a number of measures; health status is one example. As MCID measures are population estimates, individual benefits may occur below the mean scores. This IMPACT post hoc analysis assessed the likelihood of achieving health status stabilisation as a measure of DS, according to different thresholds. <bold>Methods:</bold> IMPACT compared FF/UMEC/VI 100/62.5/25µg (n=4151) vs FF/VI 100/25µg (n=4134) and UMEC/VI 62.5/25µg (n=2070). Health status was assessed as a DS measure, exploring two thresholds: no worsening from baseline (≤0), and improvement from baseline (MCID CAT ≤2, SGRQ ≤4), in CAT and SGRQ total scores. FF/UMEC/VI was compared vs FF/VI or UMEC/VI at Weeks 4, 28 and 52. <bold>Results:</bold> Patients receiving FF/UMEC/VI had significantly greater odds of achieving health status stabilisation vs FF/VI or UMEC/VI regardless of the threshold, at all timepoints (Week 52: <bold>Figure</bold>). <bold>Conclusion:</bold> FF/UMEC/VI resulted in a greater proportion of patients with health status benefits over dual therapy even below the MCID threshold of ≤4 and ≤2 unit improvement in SGRQ and CAT scores, providing support for different thresholds in DS measures. Further analyses are needed to evaluate DS as a treatment goal and validate health status as a DS measure. <bold>Funding:</bold> GSK (CTT116855/<ext-link>NCT02164513</ext-link>) <fig><object-id>erj;64/suppl_68/PA1173/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>